Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 11/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 8/20 | 1.00 |
| ▸ | CSNK2B | P67870 | 8/20 | 1.00 |
| ▸ | SGK1 | O00141 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3866680 | 0.98 | CSNK2A1 (0.96) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL10323132 | 0.72 | PIM1 (1.00) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL1817323 | 0.71 | CSNK2A1 (0.54) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL1759407 | 0.70 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL1816869 | 0.70 | CSNK2A1 (0.53) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL1760582 | 0.67 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL3866440 | 0.67 | CSNK2A1 (0.60) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL3867762 | 0.67 | CSNK2A1 (0.60) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 | |
| SCHEMBL1759675 | 0.67 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BPIM1 | |
| SCHEMBL3868111 | 0.67 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BSGK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117736151-A | Ligand compound of E3 ubiquitin ligase CDC20 and application thereof | 南京奥瑞药业有限公司 | 2024-03-22 | — | — | CN | claimed |
| EP-3352794-B1 | COMBINATION OF A PROTEIN KINASE CK2 INHIBITOR AND AN ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE INHIBITOR FOR TREATING RENAL CELL CARCINOMA | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2020-10-14 | — | — | EP | claimed |
| US-10322133-B2 | Synthetic lethal drug combination for treating renal cell carcinoma | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-06-18 | — | — | US | claimed |
| US-20180256587-A1 | A Synthetic Lethal Drug Combination for Treating Renal Cell Carcinoma | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-09-13 | — | — | US | claimed |
| US-9182385-B2 | Methods for diagnosis, prognosis and methods of treatment | NODALITY, INC. (US) | 2015-11-10 | — | — | US | claimed |
| US-8778620-B2 | Methods for diagnosis, prognosis and methods of treatment | NODALITY, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130130279-A1 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT | NODALITY, INC. (US) | 2013-05-23 | — | — | US | claimed |
| US-20120309029-A1 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT | NODALITY, INC. (US) | 2012-12-06 | — | — | US | claimed |
| US-8227202-B2 | Methods for diagnosis, prognosis and methods of treatment | NODALITY, INC. (US) | 2012-07-24 | — | — | US | claimed |
| US-8133913-B2 | Substituted indeno [1,2-b]indole derivatives as novel inhibitors of protein kinase CK2 and their use as tumor therapeutic agents, cytostatics and diagnostic aids | Heinrich-Heine Universitat Dusseldof (DE) | 2012-03-13 | — | — | US | claimed |
| WO-2010006291-A1 | METHODS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT | NODALITY, INC. (US) | 2010-01-14 | — | — | WO | claimed |
| US-20100009364-A1 | Methods for diagnosis, prognosis and methods of treatment | NODALITY, INC. (US) | 2010-01-14 | — | — | US | claimed |
| US-20090239921-A1 | METHODS FOR TREATING NEOPLASMS WITH DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE | SELVITA SP. Z.O.O. (PL) | 2009-09-24 | — | — | US | claimed |
| US-7528259-B2 | Derivatives of 4,5,6,7-tetrabromobenzimidazole and method of their preparation | SELVITA SP. Z O. O. (PL) | 2009-05-05 | — | — | US | claimed |
| US-20090098594-A1 | Methods for diagnosis prognosis and methods of treatment | NODALITY, INC. (US) | 2009-04-16 | — | — | US | claimed |
| WO-2009032213-A1 | CONTROL OF MALIGNANT CELLS BY KINASE INHIBITION | CLEVELAND STATE UNIVERSITY (US) | 2009-03-12 | — | — | WO | claimed |
| US-20090054507-A1 | CONTROL OF MALIGNANT CELLS BY KINASE INHIBITION | CLEVELAND STATE UNIVERSITY (US) | 2009-02-26 | — | — | US | claimed |
| WO-2009025847-A2 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT | NODALITY, INC. (US) | 2009-02-26 | — | — | WO | claimed |
| WO-2008033308-A2 | CONTROL OF MALIGNANT CELLS PROLIFERATION THROUGH THE INHIBITION OF CASEIN KINASE 2 | CLEVELAND STATE UNIVERSITY (US) | 2008-03-20 | — | — | WO | claimed |
| US-20070213385-A1 | NEW DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE AND METHOD OF THEIR PREPARATION | SELVITA S.A. (PL) | 2007-09-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054507-A1 | CONTROL OF MALIGNANT CELLS BY KINASE INHIBITION | CSNK2A2, CSNK1G2, PACSIN2 | CSNK2A1 4/4885CSNK2A2 1/4885CSNK2B 6/4885 |
| US-20070213385-A1 | NEW DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE AND METHOD OF THEIR PREPARATION | CYP3A4, IL4I1, CYP4B1 | CSNK2A1 1059/4885CSNK2A2 1023/4885CSNK2B 840/4885 |
| US-20090239921-A1 | METHODS FOR TREATING NEOPLASMS WITH DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE | CSNK2A2, CSNK2A1, CSNK2B | CSNK2A1 2/4885CSNK2A2 1/4885CSNK2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.